Absci Corp (ABSI) Q1 2025 Earnings Call Highlights: Transition to Clinical Stage and Strong ...
Research and Development Expenses: $16.4 million for Q1 2025, up from $12.2 million in the prior year period.
Selling, General and Administrative Expenses: $9.5 million for Q1 2025, compared to $8.7 million in the prior year period.
Cash, Cash Equivalents, and Short-term Investments: $134 million as of March 31, 2025, up from $112.4 million as of December 31, 2024.
Projected Cash Runway: Sufficient to fund operations into the first half of 2027.
Warning! GuruFocus has detected 4 Warning Signs with ABSI.
Release Date: May 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Absci Corp (NASDAQ:ABSI) has initiated its first in-human clinical trial for ABS-101, marking its transition to a clinical-stage biotech company.
The company has a robust pipeline, including ABS-201 for androgenetic alopecia, which shows promising pre-clinical results and is advancing towards clinical trials.
ABS-101 has demonstrated high affinity, potency, and low immunogenicity in pre-clinical studies, with interest from potential partners.
Absci Corp (NASDAQ:ABSI) is leveraging its AI platform to rapidly engineer therapeutics, showcasing its capability to design novel antibodies.
The company has a strong financial position with $134 million in cash and investments, sufficient to fund operations into the first half of 2027.
Research and development expenses increased significantly to $16.4 million, driven by internal program advancements and personnel costs.
The company reported a relatively low revenue of $1.2 million for the first quarter, indicating a reliance on future partnerships and collaborations.
There is uncertainty regarding the timeline for nominating a drug candidate for ABS-301, as in vivo studies are still ongoing.
The competitive landscape for ABS-501, targeting HER2, is crowded, posing challenges for differentiation.
Absci Corp (NASDAQ:ABSI) has not disclosed specific timelines for potential milestones or partnerships, creating uncertainty for investors.
Q: Regarding ABS-101, what are you hoping to see in the Phase 1 top line in the second half of the year in terms of decay and immunogenicity endpoints as well as any other metrics you may be looking at? A: Sean McClain, CEO: We're looking for a strong safety profile and target engagement similar to previous data. Christian Stegmann, SVP of Drug Creation, added that they aim to validate the extended half-life and low immunogenicity, demonstrating target engagement over an extended period.
Q: Regarding ABS-201, do you think this product can potentially be self-administered in the future? A: Sean McClain, CEO: Yes, we believe it can be self-administered eventually. Initially, we plan to work with dermatologists to ensure effective administration.
Q: How are you thinking about potential market segmentation for ABS-201? A: Zach Jonasson, CFO: We believe the mechanism could be efficacious across various segments of androgenetic alopecia. We plan to explore this in a Phase 1 trial with a broad age range and both genders. Christian Stegmann added that there is potential beyond alopecia, such as in endometriosis.
Q: Can you provide initial thoughts on the type of dosing for ABS-201 in humans and systemic exposure observed in the NHP model? A: Christian Stegmann, SVP of Drug Creation: We anticipate dosing every 8 to 12 weeks, which is attractive for androgenetic alopecia. Full pharmacokinetic data will be disclosed later at a scientific venue.
Q: When can we expect the development candidate for ABS-301 to be shared? A: Sean McClain, CEO: We are progressing towards a drug candidate and are currently conducting in vivo studies. We have not disclosed a specific timeline for the candidate nomination.
Q: Can you elaborate on the combo strategy with ABS-101 and the partnership with AstraZeneca? A: Sean McClain, CEO: We see a trend towards combo-based approaches, which could enhance efficacy and durability. We are pursuing a bi-specific strategy with a novel arm. Zach Jonasson, CFO, noted that specific partnership details are confidential.
Q: As ABS-101 and ABS-201 progress, how do you view future partnerships and cost structure flexibility? A: Zach Jonasson, CFO: We anticipate improved deal terms due to platform validation and advancements. We continually seek efficiencies in our AI platform to optimize resource allocation and cost structure.
Q: How does Absci plan to leverage AI for safety predictions as the FDA shifts towards minimizing animal use? A: Sean McClain, CEO: We are excited about the FDA's direction and believe our AI models, like the naturalness model, provide a significant advantage in reducing immunogenicity and aligning with regulatory trends.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Biesse SpA (FRA:BI2) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Sales: EUR323 million, a decrease of EUR73 million or 18% compared to last year. EBITDA Adjusted: EUR16 million, a decrease of EUR70 million compared to the same period last year. Net Result: Negative EUR7 million, compared to a positive EUR4 million last year. Order Intakes: EUR315 million, down approximately 10% from last year. Backlog: EUR250 million, lower compared to December. Head Count: 3,700 employees, reduced by more than 500 from last year. Net Financial Position: Positive EUR5 million, down from EUR25 million in December. Gross Margin: Improved in H1 2025, expected to remain stable with a slight decline in the next half. G&A and Labor Costs: Significant reductions contributing to improved EBITDA in Q2. Warning! GuruFocus has detected 4 Warning Sign with FRA:BI2. Release Date: August 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biesse SpA (FRA:BI2) reported a significantly improved EBITDA in Q2 compared to Q1, attributed to cost-saving measures in G&A and labor costs. The company achieved a higher gross profit margin in the first half of 2025 compared to the previous year, indicating effective cost management. Biesse SpA (FRA:BI2) plans to strengthen its commercial and services structure globally, which could enhance market penetration and customer service. The company is focusing on developing new products with advanced features, which could drive future growth and competitiveness. Despite a challenging economic environment, Biesse SpA (FRA:BI2) maintains a strong equity position of over EUR244 million, reflecting financial stability. Negative Points Biesse SpA (FRA:BI2) experienced an 18% decline in sales in the first half of 2025, with significant impacts in EMEA, America, and APAC regions. The company posted a net loss of EUR7 million for the first half of 2025, compared to a positive result in the same period last year. Order intake decreased by approximately 10% year-over-year, with a notable impact from the US market due to tariff uncertainties. The backlog has decreased to EUR250 million, reflecting a lower order volume compared to previous periods. Challenges in customer access to bank credit have led to postponed machine deliveries, affecting revenue recognition and inventory levels. Q & A Highlights Q: Can you provide more details on the order intake, especially regarding the US market's wait-and-see approach and the impact of the 15% duty? A: Nicola Sautto, CFO, explained that the wait-and-see approach significantly affected Q2, with a 10% decline in order intake. The US market was particularly impacted. However, with the new 15% tariff in place, there is renewed confidence among clients. Biesse is adjusting its pricing strategy and expects to recover from this impact. There are no significant competitors with a local supply chain in the US, so Biesse remains optimistic about regaining normal order intake levels. Q: Given the reductions in labor and G&A costs, can these be considered a baseline for 2025 and 2026 projections? A: Nicola Sautto noted that the G&A reductions seen in the first half could be doubled to estimate the full-year impact. Additional reductions are expected in 2026 due to ongoing initiatives. However, labor costs might increase as Biesse plans to strengthen its commercial, service, and product departments, which will involve hiring more staff. Q: Is the decision to hire more people in commercial, service, and production departments indicative of a recovery expectation for next year? A: Nicola Sautto confirmed that Biesse expects to have a better second half compared to the first. The decision to hire is driven by a need to better cover markets and develop new products. While no recovery signals were evident in the first half, the leadership team is confident about future prospects and is investing in people and commercial strategies. Q: How does Biesse plan to handle the impact of tariffs between the US and India, given the production of machines in India? A: Nicola Sautto mentioned that Biesse is evaluating the potential 25% tariff impact on machines produced in India and shipped to the US. The company is considering strategies to mitigate this impact, although the 15% tariff on machines from Italy to the US is expected to stabilize the situation. Q: What is the current status of Biesse's backlog, and how does it compare to previous periods? A: The backlog stands at EUR250 million, which is lower than December figures due to seasonal trends. Typically, the second half of the year sees an increase in orders, so the current backlog is consistent with historical patterns. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
9 hours ago
- Yahoo
Linde PLC (LIN) Q2 2025 Earnings Call Highlights: Record EPS and Operating Margin Amidst ...
EPS: $4.09, representing a 6% increase from the prior year. Operating Margin: 30.1%, an all-time quarterly high, increased by 80 basis points year-over-year. Operating Cash Flow: Grew 15% year-over-year. Return on Capital (ROC): 25.1%, leading the industry. Sales: $8.5 billion, a 3% increase over the prior year and 5% sequentially. Underlying Sales Growth: 1% over the prior year and 3% sequentially, excluding acquisitions and FX impacts. Volume Change: Down 1% from last year, with a 2% sequential increase. Acquisitions Impact: Lifted sales by 1% over the prior year. Capital Allocation: $6.5 billion deployed year-to-date, with $2.8 billion in investments meeting risk-reward criteria. Guidance for Q3 EPS: $4.10 to $4.20, representing 4% to 7% growth over last year. Full Year EPS Guidance: $16.30 to $16.50, indicating 5% to 6% growth, including a 1% currency tailwind. Warning! GuruFocus has detected 6 Warning Signs with LBTYA. Release Date: August 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Linde PLC (NASDAQ:LIN) achieved record quarterly EPS of $4.09 and an operating margin of 30.1%, despite a challenging macro environment. Operating cash flows grew by 15%, and the return on capital (ROC) of 25.1% continues to lead the industry. The sale of gas project backlog has doubled over four years, reaching $7.1 billion, with significant turnover and execution. Linde PLC (NASDAQ:LIN) has strong customer commitments in the space sector, supporting double-digit growth in commercial space launches. The company maintains a disciplined capital allocation policy, deploying $6.5 billion year-to-date, with a focus on investments that meet risk-reward criteria. Negative Points Volumes are down 1% from last year, primarily due to weaker base volumes in EMEA, offsetting contributions from the project backlog. Europe is expected to continue experiencing softening demand, particularly in Western Europe, with no catalyst for economic improvement this year. The electronics end market faces challenges, with helium pricing down high single digits due to oversupply, particularly in Asia. Linde PLC (NASDAQ:LIN) remains cautious about the economic outlook, with guidance reflecting potential economic contraction and currency volatility. The company faces challenges in Europe due to de-industrialization and potential plant closures, impacting long-term growth prospects. Q & A Highlights Q: Can you provide insights into the geographical and end-market performance expectations for the rest of the year? A: Sanjiv Lamba, CEO, explained that in the Americas, volumes are expected to be flat or slightly up, driven by resilient end markets like space launches, while Europe is likely to see continued demand softening, particularly in Western Europe. In Asia, China is expected to remain flat, with growth in EVs and electronics offset by weaker metals and chemicals. India shows strong growth potential, while the overall APAC region is expected to be flat. Q: Is there a risk of not achieving future price increases given the current weak macroeconomic environment? A: Sanjiv Lamba, CEO, stated that Linde has consistently achieved positive pricing over the last 25 years, even through economic cycles. He expects this trend to continue, with pricing tracking globally weighted CPI, except for some challenges in China, particularly with helium pricing. Q: Can you explain the margin performance in the Americas compared to other segments? A: Matthew White, CFO, noted that while margins in the Americas were flat year-over-year, there is room for improvement. He attributed the flat margins to some mix effects, including home care, and emphasized the importance of tracking full-year performance rather than focusing on quarterly fluctuations. Q: What is the outlook for Linde's project backlog given the current macroeconomic conditions? A: Sanjiv Lamba, CEO, expressed confidence that Linde's project backlog will end the year with a "7" handle, despite starting up $1 billion of investments in the second half. He highlighted a strong opportunity pipeline and expects to bring in enough projects to maintain the backlog above $7 billion. Q: How is Linde positioned in the space industry, and what is the growth potential? A: Sanjiv Lamba, CEO, highlighted that Linde is well-positioned in the space industry, supplying more than four out of five launches in the US. The company has invested significantly in infrastructure to support the space ecosystem, with revenue from the commercial space segment quadrupling over the last three years. Linde expects continued growth in this sector. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
17 hours ago
- Hamilton Spectator
The Keg Royalties Income Fund Obtains Unitholder Approval for the Transaction with Fairfax
Not for distribution to U.S. News wire services or dissemination in the U.S. VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the 'Fund') (TSX: is pleased to announce that, at its special meeting ('Meeting') of the unitholders ('Unitholders') and holders of securities exchangeable into units (the 'Exchangeable Unitholders') of the Fund (the 'Units') held earlier today, Unitholders and Exchangeable Unitholders voted overwhelmingly in favour of the proposed acquisition by 1543965 B.C. Ltd. (the 'Purchaser'), a subsidiary of Fairfax Financial Holdings Limited (the 'Parent') of all of the issued and outstanding units of the Fund not otherwise owned by it and its affiliates (collectively, 'Fairfax') for a price of $18.60 per Unit (the 'Consideration'), payable in cash by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia) in accordance with the arrangement agreement dated June 16, 2025 among the Fund, the Purchaser and the Parent (the 'Arrangement Agreement', and such acquisition and the other transactions contemplated in the Arrangement Agreement, the 'Transaction'). The Arrangement Agreement provides that in addition to the Consideration, Unitholders will be entitled to receive a prorated monthly distribution for the month in which the closing occurs, as well as a special cash distribution based on the Fund's historical practice of paying annual special distributions, with such special cash distribution being set at $0.055 per Unit for the 2025 fiscal year, prorated for the portion of the fiscal year completed as of the closing of the Transaction. The Transaction required the approval of (a) more than two thirds of the votes cast by Unitholders (including for this purpose Exchangeable Unitholders) present in person or represented by proxy at the Meeting, and (b) a simple majority of the votes cast by Unitholders present in person or represented by proxy at the Meeting, excluding the votes of Fairfax and any other Unitholders whose votes were required to be excluded for the purposes of 'minority approval' under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). Of the votes cast at the Meeting with respect to the Transaction, 99.42% were voted in favour of the Transaction. In addition, of the votes cast at the Meeting with respect to the Transaction, excluding those votes required to be excluded pursuant to MI 61-101, 98.79% were voted in favour of the Transaction. A report of voting results for the Meeting will be available on the SEDAR+ profile of the Fund at . The Transaction is structured as a statutory plan of arrangement under the Business Corporations Act (British Columbia) . The Fund and Fairfax intend to seek a final order from the Supreme Court of British Columbia to approve the plan of arrangement on August 7, 2025 (the 'Final Order'). Completion of the Transaction remains subject to the satisfaction or waiver of certain customary closing conditions, including the receipt of the Final Order. Subject to the satisfaction or waiver of all conditions to the Transaction, the Transaction is expected to be completed on or about August 13, 2025. It is expected that the Units will be delisted from the Toronto Stock Exchange in connection with the Transaction. Forward Looking Information This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities laws. This information includes, but is not limited to, statements concerning the Fund's objectives, its strategies to achieve those objectives, as well as statements made with respect to the trustees of the Fund's (the 'Trustees') beliefs, plans, estimates, projections and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as 'expects', 'estimates', 'intends', 'anticipates', 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might', 'will', 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Trustees' expectations, estimates and projections regarding future events or circumstances. Forward-looking information in this news release, which includes, among other things, statements relating to the closing of the Transaction, the timing thereof and the conditions thereto, including the seeking of the Final Order and the expected delisting of the Units, is necessarily based on a number of opinions and assumptions that the Trustees considered appropriate and reasonable as of the date such statements are made in light of their experience, current conditions and expected future developments. Risks and uncertainties related to the Transaction include, but are not limited to: the possibility that the Transaction will not be completed on the terms and conditions currently contemplated; failure of the Fund and Fairfax to obtain the required court approval for, or satisfy other conditions to effect, the Transaction; and other risk factors contained in filings made by the Fund with the Canadian securities regulators, including the Fund's annual information form dated March 25, 2025 and financial statements and related management discussion and analysis for the financial year ended December 31, 2024 filed with the securities regulatory authorities in certain jurisdictions of Canada and available at . Although the Trustees have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to them or that they presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this news release represents the Fund's expectations as of the date of this news release (or as the date they are otherwise stated to be made) and are subject to change after such date. However, the Fund disclaims any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. All of the forward-looking information contained in this news release is expressly qualified by the foregoing cautionary statements. About The Keg Royalties Income Fund The Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual property used by Keg Restaurants Ltd. ('KRL'). Vancouver-based KRL is the leading operator and franchisor of steakhouse restaurants in Canada and has a substantial presence in select regional markets in the United States. KRL has been named the number one restaurant company to work for in Canada in the latest edition of Forbes 'Canada's Best Employers 2025' survey. About Fairfax Financial Holdings Limited Fairfax Financial Holdings Limited is a holding company which, through its subsidiaries, is primarily engaged in property and casualty insurance and reinsurance and the associated investment management.
